These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [A gastroenterology unit experience with adjuvant chemotherapy for non-metastatic colon cancer: results from 24 cases]. Belhadj N; Gargouri D; Kharrat J; Ben Hriz F; Kochlef A; Kilani A; Romani M; Ghorbel A; Cherif R; Khlifi S; Ben Maamer A; Letaief A Tunis Med; 2003 Jun; 81(6):395-9. PubMed ID: 14534945 [TBL] [Abstract][Full Text] [Related]
44. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Elsaleh H; Powell B; Soontrapornchai P; Joseph D; Goria F; Spry N; Iacopetta B Oncology; 2000; 58(1):52-9. PubMed ID: 10644941 [TBL] [Abstract][Full Text] [Related]
45. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1. Staib L; Link KH; Beger HG; J Gastrointest Surg; 2001; 5(3):275-81. PubMed ID: 11419451 [TBL] [Abstract][Full Text] [Related]
46. Adjuvant therapy for colon cancer in the new millenium. Rao S; Cunningham D Scand J Surg; 2003; 92(1):57-64. PubMed ID: 12705552 [TBL] [Abstract][Full Text] [Related]
47. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience. Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744 [TBL] [Abstract][Full Text] [Related]
48. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627 [TBL] [Abstract][Full Text] [Related]
49. Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication. Bancewicz J; Calman KC; Macpherson SG; McArdle CS; McVie JG; Soukop M J R Soc Med; 1980 Mar; 73(3):197-9. PubMed ID: 7014886 [TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy. Kamoshida S; Matsuoka H; Ishikawa T; Maeda K; Shimomura R; Inada K; Tsutsumi Y Jpn J Clin Oncol; 2004 Oct; 34(10):594-601. PubMed ID: 15591457 [TBL] [Abstract][Full Text] [Related]
55. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. Link KH; Kornmann M; Staib L; Redenbacher M; Kron M; Beger HG; Ann Surg; 2005 Aug; 242(2):178-87. PubMed ID: 16041207 [TBL] [Abstract][Full Text] [Related]
56. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma. Luppi G; Zoboli A; Barbieri F; Crisi G; Piccinini L; Silingardi V Ann Oncol; 1996 Apr; 7(4):412-5. PubMed ID: 8805935 [TBL] [Abstract][Full Text] [Related]
57. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C; Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678 [TBL] [Abstract][Full Text] [Related]